Pharmaceuticals

DiscGenics to Present at 40th Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 6, 2022 /PRNewswire/ -- DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that Chie...

2022-01-06 09:05 3135

IND Approved for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer

SUZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that the IND application for the pivotal clinical trial (KN026-CSP-001) of the anti-HER2 bispecific antibody KN026 combined with che...

2022-01-05 11:49 5303

SI GROUP APPOINTS RUSTOM JILLA AS NEW CHIEF FINANCIAL OFFICER

Jilla brings nearly 20 years of international CFO experience including transformational change SCHENECTADY, N.Y., Jan. 5, 2022 /PRNewswire/ -- SI Group, a leading performance additives company, announced today the appointment ofRustom Jilla as its Senior Vice President and Chief Financial Office...

2022-01-05 02:00 4181

CAI Announces CEO Succession

INDIANAPOLIS, Jan. 4, 2022 /PRNewswire/ -- CAI, a global consulting company that provides technical, operational consulting, and project management services to life sciences, data centers, and industrial process manufacturing industries, today announcedMichael Martin, CAI President, will succeed ...

2022-01-04 22:33 5989

Alamar Biosciences partners with Abcam to drive understanding of the human proteome

FREMONT, Calif. and CAMBRIDGE, England, Jan. 4, 2022 /PRNewswire/ -- Alamar Biosciences  (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC...

2022-01-04 17:00 3076

Breakthrough Discoveries on Novel Features of Omicron Variant and An Anti-Omicron Antibody JMB2002

SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Joint research results from Biologics of Jemincare and Shanghai Institute ofMateria Medica (SIMM) of Chinese Academy of Sciences (CAS) confirmed that JMB2002, an anti-SARS-CoV-2 neutralizing antibody (NAb) discovered by Biologics of Jemincare is still effect...

2022-01-04 10:00 5406

Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer

SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products inAsia, announced today that T...

2022-01-04 08:00 5257

Sihuan Pharmaceutical (0460.HK): Sunshine Life Insurance Leads Investment in Xuanzhu Biopharm

HONG KONG, Jan. 3, 2022 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460) is pleased to announce that, its subsidiary Xuanzhu...

2022-01-03 14:24 8023

Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus

- Ritonavir oral tablet annual production capacity has been expanded to 100 million tablets and can be further rapidly expanded based on market demand - ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection - ASC11 is ...

2022-01-03 08:30 4852

CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration

SUZHOU, China, Jan. 3, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the investigational new ...

2022-01-03 08:00 5132

Seegene Airlifts 1.7 million COVID-19 Tests to Israel Battling the Omicron Variant by a charter plane

* On December 29, Seegene to deliver Allplex™ SARS-CoV-2 Master Assay that can preemptively detect the Omicron variant at the primary screening stage * Earlier this month, the company has hired a private plane to deliver 2.8 million COVID-19 diagnostic tests to European countries includingItal...

2021-12-29 19:00 5312

DoctorOnCall Offers Free Medical Assistance To Flood Victims

KUALA LUMPUR, Malaysia, Dec. 29, 2021 /PRNewswire/ -- Amidst Malaysia's worst flash flooding following heavy rains over the weekend that displaced tens of thousands of people,Malaysia's first and largest digital health platform, DoctorOnCall, has announced a flood relief medical assistance initia...

2021-12-29 11:30 4926

VISTA Eye Specialist resolved to be a Changemaker and A Force for Good with B Corp Certification.

PETALING JAYA, Malaysia, Dec. 29, 2021 /PRNewswire/ -- VISTA Eye Specialist (VISTA) believes that being one of the leading eye specialists is not just about medical care. "As part of our mission statement, we believe that other than to safely help people see their best, our goal is about changing...

2021-12-29 08:00 3268

Muslim-Friendly Malaysia Showcases Healthcare Excellence at Expo 2020 Dubai

DUBAI, UAE, Dec. 28, 2021 /PRNewswire/ -- Malaysia Healthcare, will be showcasing its excellence in healthcare service delivery and providing seamless healthcare journey experiences during Week 14 of Expo 2020 Dubai. From 2nd - 8th January 2022, expo participants can visit the Malaysia Pavilion to...

2021-12-28 15:00 2301

CStone announced new drug approval of precision therapy AYVAKIT® (avapritinib) in Hong Kong, China for the treatment of PDGFRA D842V mutant gastrointestinal stromal tumors (GIST)

* AYVAKIT is the first precision therapy approved in Hong Kong, China for the treatment of patients with PDGFRA D842V mutant GIST * This is CStone's fifth NDA approval in Greater China this year SUZHOU, China ,Dec. 28, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...

2021-12-28 08:00 4924

ChemRar Group announces the Russian Avifavir® drug is effective against variants of COVID-19, including Delta and Omicron

Avifavir® is effective against various variants of coronavirus, including Delta and Omicron, as it affects the highly conservative and mutation-resistant replication systems of RNA virus (RdRp). The virus is incapable of developing resistance to favipiravir even with long-term exposure on infect...

2021-12-27 21:20 3832

Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B

DURHAM, N.C. and BEIJING, Dec. 27, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public healt...

2021-12-27 18:45 4793

COVID-19 Vaccine Developed by WestVac BioPharma Has High Titer Neutralizing Antibodies Against Omicron

CHENGDU, China, Dec. 24, 2021 /PRNewswire/ -- WestVac BioPharma Co., Ltd. has achieved a significant progress in the second generation COVID-19 vaccine against the Omicron mutant strain. The vaccine belongs to the latest fifth generation vaccine technology, targeting the S-RBD protein of the COV...

2021-12-24 19:57 8362

Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer who Progressed after EGFR-TKI Therapy

SAN FRANCISCO and SUZHOU, China, Dec. 24, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-12-24 16:51 11512

Novavax and SK bioscience Expand Manufacturing Agreement

- Novavax secures additional manufacturing capacity through 2022 - SK bioscience secures long-term license to supply NVX-CoV2373 for the Korean market GAITHERSBURG, Md., Dec. 24, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializin...

2021-12-24 07:30 4301
1 ... 170171172173174175176 ... 184